| Name | Title | Contact Details |
|---|---|---|
Randall Spencer |
VP of Product Innovation | Profile |
Kate Surdez |
Chief Human Resources Officer | Profile |
Doug Rice |
Chief Financial Officer | Profile |
Peter Carlson |
Chief Financial Officer | Profile |
Peter Carlson |
Chief Financial Officer | Profile |
The company`s proprietary CTreg™ (cryopreservation for Tregs) system is the first in the industry to create an `off the shelf` approach to Treg cell therapy allowing for serial infusions. Through our patented TAI™ (Tregs Against Inflammation) and EAI™ (Exosomes Against Inflammation) platforms , Coya is focused on the advancement of disease modifying approaches to address the significant unmet medical needs of patients with ALS, Parkinson`s, Alzheimer`s, FTD and autoimmune diseases.
Allena Pharmaceuticals is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. Allena`s proprietary technological approach enables the design, formulation and delivery of non-absorbed and stable enzymes orally and in sufficient doses for activity in the GI tract. This approach utilizes the GI tract to degrade metabolites, such as oxalate and urate, reducing plasma and urine levels, and in turn, reducing their disease burden on the kidney over time.
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets.
JBJS is a Needham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
IU Health is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.